Studies have highlighted that patients exhibiting an unpigmented phenotype in advanced connective tissue-promoting proliferative melanoma exhibit enhanced immunotherapeutic responses to PD-1 or PDL1 immune checkpoint blockade therapies58. The gene discussed is CD274; the disease is melanoma.